🔎 Trials Near Me

Почетна › Hronična limfocitna leukemija › Florida › Jacksonville

Kliničke studije za Hronična limfocitna leukemija u gradu Jacksonville, FL

11 studija za Hronična limfocitna leukemija traži učesnike na lokacijama u gradu Jacksonville i okolini (u krugu od oko 30 milja). Otvorite studiju da biste videli ko može da učestvuje i kako kontaktirati tim studije.

Zvanični tekst studije (na engleskom)

Tražite učesnike za studiju? Istaknite je na vrhu ove stranice — $99 za 30 dana →

A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

Тражи се учесникФаза 3
  • Baptist Md Anderson Cancer Center, Jacksonville
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT06846671

A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Тражи се учесникФаза 4
  • Cancer Specialists, LLC, Jacksonville
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT07218341

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

Тражи се учесникФаза 1/2
  • Mayo Clinic, Clinical Trials Referral Office, Jacksonville
Узраст од 13 до 90 · Оба пола · Ажурирано 26. 10. 2026. · NCT06533579

Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

Тражи се учесникФаза 3
  • Mayo Clinic - Jacksonville, Jacksonville
Узраст 18 и старији · Оба пола · Ажурирано 14. 10. 2026. · NCT07648264

A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

Тражи се учесникФаза 1/2
  • Mayo Clinic Jacksonville, Jacksonville
Узраст 18 и старији · Оба пола · Ажурирано 5. 10. 2026. · NCT05006716

A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia

Тражи се учесникФаза 3
  • Mayo Clinic Jacksonville, Jacksonville
Узраст 18 и старији · Оба пола · Ажурирано 28. 9. 2026. · NCT07277231

A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Тражи се учесникФаза 3
  • Mayo Clinic Jacksonville, Jacksonville
  • Cancer Specialists of North Florida, Jacksonville
Узраст 18 и старији · Оба пола · Ажурирано 28. 9. 2026. · NCT06973187

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

Тражи се учесникФаза 1/2
  • Mayo Clinic, Jacksonville
Узраст 12 и старији · Оба пола · Ажурирано 3. 9. 2026. · NCT04588922

A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Тражи се учесникФаза 3
  • Cancer Specialists of North Florida - Jacksonville - AC Skinner Parkway /ID# 266713, Jacksonville
Узраст 18 и старији · Оба пола · Ажурирано 9. 4. 2026. · NCT06428019

A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib

Тражи се учесникФаза 4
  • Cancer Specialists, LLC, Jacksonville
Узраст 18 и старији · Оба пола · Ажурирано 2. 3. 2026. · NCT06876649

B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies

Тражи се учесникФаза 1
  • Mayo Clinic in Florida, Jacksonville
Узраст 18 и старији · Оба пола · Ажурирано 13. 2. 2026. · NCT06191887

Studije za Hronična limfocitna leukemija u drugim gradovima

Ostale studije u gradu Jacksonville

Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.